Skip to Main content Skip to Navigation
Journal articles

Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?

Abstract : In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.
Complete list of metadatas

Cited literature [10 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-02517857
Contributor : Isabelle Combe <>
Submitted on : Thursday, May 7, 2020 - 4:43:51 PM
Last modification on : Tuesday, May 12, 2020 - 1:20:26 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2020-10-01

Please log in to resquest access to the document

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

Citation

Sophie Alexandra Baron, Christian Devaux, Philippe Colson, Didier Raoult, Jean-Marc Rolain. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?. International Journal of Antimicrobial Agents, Elsevier, 2020, pp.105944. ⟨10.1016/j.ijantimicag.2020.105944⟩. ⟨hal-02517857⟩

Share

Metrics

Record views

454